Aktiesnakken — Juli 2012
-
Roche meet guidance
http://www.roche.com/media/media_releases/med-cor-2012-07-26.htm -
MabThera/Rituxan. For non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis
(RA). Sales growth in the oncology franchise of 9% was driven by the uptake of the new first-line maintenance indication in
follicular lymphoma (a type of NHL) in the US and Europe. US sales were 1.6 billion Swiss francs, an increase of 8%, while
sales in Western Europe were up by 6%. Sales grew by 13% in the International region, particularly in China and Brazil, due
to growth in all
Her må Arzerra da gerne spise med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind